Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer

NCT00593697 is registered in ClinicalTrials.gov with Finnish Breast Cancer Group as lead sponsor.

NCT NCT00593697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00593697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer
Lead sponsor
Finnish Breast Cancer Group
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
November 30, 2014
Enrollment
2,168 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms